The efficiency of low-dose hepatitis B immunoglobulin plus nucleos(t)ide analogs in preventing posttransplant hepatitis B virus recurrence
Adult
Antiviral Agents
/ administration & dosage
Carcinoma, Hepatocellular
/ surgery
Female
Hepatitis B
/ drug therapy
Humans
Immunoglobulins
/ administration & dosage
Liver Neoplasms
/ surgery
Liver Transplantation
/ adverse effects
Male
Middle Aged
Nucleic Acid Synthesis Inhibitors
/ administration & dosage
Postoperative Complications
/ drug therapy
Recurrence
Retrospective Studies
Liver transplantation
Hepatitis B immunoglobulin
dose
recurrence
Journal
Turkish journal of medical sciences
ISSN: 1303-6165
Titre abrégé: Turk J Med Sci
Pays: Turkey
ID NLM: 9441758
Informations de publication
Date de publication:
08 08 2019
08 08 2019
Historique:
entrez:
7
8
2019
pubmed:
7
8
2019
medline:
19
2
2020
Statut:
epublish
Résumé
In this study, the efficiency of using low-dose hepatitis B immunoglobulin (HBIG) plus antiviral treatment according to individual needs has been evaluated in posttransplant hepatitis B virus (HBV) patients. We retrospectively evaluated 179 patients who were admitted between 2009 and 2014. Five thousand IU intravenous HBIG was given in the anhepatic phase, and 400 IU/day intramuscular (IM) HBIG was given in the posttransplant period. After HBsAg seroconversion, 400 IU IM HBIG was continued as prophylaxis every two weeks. The average follow-up period was 26 (2–65) months. Seventy patients had hepatocellular carcinoma (HCC). The HBV recurrence was 4.5% in the first year, and 5.8% in the third year. The HBsAg became negative in 11 (2–63) days, and anti-HBs became positive in 9 (1–31) days. HBsAg positivity occurred in 6 patients during the follow-up period. Five of these patients were those who underwent transplantation due to HCC. In 5 of the HCC patients, in whom HBsAg became positive, tumor recurrence was observed after 0.3–9.9 months. HBsAg positivity was more frequently detected in patients with HCC (P = 0.009). The HBV recurrence should be evaluated as a predictor of the HCC recurrence in patients who were transplanted due to HCC.
Sections du résumé
Background/aim
In this study, the efficiency of using low-dose hepatitis B immunoglobulin (HBIG) plus antiviral treatment according to individual needs has been evaluated in posttransplant hepatitis B virus (HBV) patients.
Materials and methods
We retrospectively evaluated 179 patients who were admitted between 2009 and 2014. Five thousand IU intravenous HBIG was given in the anhepatic phase, and 400 IU/day intramuscular (IM) HBIG was given in the posttransplant period. After HBsAg seroconversion, 400 IU IM HBIG was continued as prophylaxis every two weeks.
Results
The average follow-up period was 26 (2–65) months. Seventy patients had hepatocellular carcinoma (HCC). The HBV recurrence was 4.5% in the first year, and 5.8% in the third year. The HBsAg became negative in 11 (2–63) days, and anti-HBs became positive in 9 (1–31) days. HBsAg positivity occurred in 6 patients during the follow-up period. Five of these patients were those who underwent transplantation due to HCC. In 5 of the HCC patients, in whom HBsAg became positive, tumor recurrence was observed after 0.3–9.9 months. HBsAg positivity was more frequently detected in patients with HCC (P = 0.009).
Conclusion
The HBV recurrence should be evaluated as a predictor of the HCC recurrence in patients who were transplanted due to HCC.
Identifiants
pubmed: 31385669
doi: 10.3906/sag-1808-86
pmc: PMC7018359
doi:
Substances chimiques
Antiviral Agents
0
Immunoglobulins
0
Nucleic Acid Synthesis Inhibitors
0
hepatitis B hyperimmune globulin
XII270YC6M
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1019-1024Informations de copyright
This work is licensed under a Creative Commons Attribution 4.0 International License.
Références
Hepatology. 2002 Jun;35(6):1528-35
pubmed: 12029640
Hepatology. 1996 Dec;24(6):1327-33
pubmed: 8938155
Liver Transpl. 2002 Oct;8(10 Suppl 1):S67-73
pubmed: 12362302
Hepatology. 2000 Dec;32(6):1189-95
pubmed: 11093723
Transplant Proc. 2008 Jul-Aug;40(6):1961-4
pubmed: 18675101
Liver Transpl. 2005 Jul;11(7):716-32
pubmed: 15973718
Med Klin (Munich). 2008 Apr 15;103(4):190-7
pubmed: 18484203
N Engl J Med. 1993 Dec 16;329(25):1842-7
pubmed: 8247035
Liver Transpl. 2000 Jul;6(4):429-33
pubmed: 10915163
Am J Transplant. 2010 Aug;10(8):1861-9
pubmed: 20659092
Hepatology. 1998 Aug;28(2):585-9
pubmed: 9696028
Liver Transpl. 2006 Feb;12(2):253-8
pubmed: 16447195
Transplant Proc. 2008 Jun;40(5):1511-7
pubmed: 18589140
Hepatobiliary Pancreat Dis Int. 2008 Aug;7(4):357-61
pubmed: 18693169
Transpl Int. 2005 May;17(12):746-58
pubmed: 15688165
Clin Transplant. 2016 Oct;30(10):1216-1221
pubmed: 27409074
Gastroenterology. 2007 Mar;132(3):931-7
pubmed: 17383422
Hepatol Int. 2012 Jun;6(3):531-61
pubmed: 26201469
Liver Transpl. 2011 Oct;17(10):1176-90
pubmed: 21656655
Am J Gastroenterol. 2003 Jan;98(1):151-9
pubmed: 12526951
Liver Transpl. 2007 Mar;13(3):334-42
pubmed: 17154401
Gastroenterology. 2008 Jun;134(7):1890-9; quiz 2155
pubmed: 18424269
Liver Int. 2008 Jan;28(1):72-8
pubmed: 17983429
Liver Transpl. 2002 Jan;8(1):2-9
pubmed: 11799479
Langenbecks Arch Surg. 2012 Jun;397(5):697-710
pubmed: 21533917
Transplant Proc. 2006 Mar;38(2):579-83
pubmed: 16549180
Gastroenterology. 2004 Jan;126(1):102-10
pubmed: 14699492
Liver Transpl. 2013 Sep;19(9):1030-5
pubmed: 23788470
J Viral Hepat. 2007 Nov;14 Suppl 1:37-44
pubmed: 17958641
Hepatology. 2002 Jan;35(1):176-81
pubmed: 11786974